Logo image of RNXT

RENOVORX INC (RNXT) Stock Price, Quote, News and Overview

NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD

1.37  -0.02 (-1.44%)

RNXT Quote, Performance and Key Statistics

RENOVORX INC

NASDAQ:RNXT (6/9/2025, 4:30:02 PM)

1.37

-0.02 (-1.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.69
52 Week Low0.75
Market Cap50.10M
Shares36.57M
Float32.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-13 2025-08-13
IPO08-17 2021-08-17


RNXT short term performance overview.The bars show the price performance of RNXT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

RNXT long term performance overview.The bars show the price performance of RNXT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30

The current stock price of RNXT is 1.37 USD. In the past month the price increased by 29.25%. In the past year, price increased by 16.1%.

RENOVORX INC / RNXT Daily stock chart

RNXT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.42 334.13B
AMGN AMGEN INC 13.97 155.93B
GILD GILEAD SCIENCES INC 14.6 140.56B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.57B
REGN REGENERON PHARMACEUTICALS 11.68 55.89B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.64B
ARGX ARGENX SE - ADR 101.5 35.64B
ONC BEONE MEDICINES LTD-ADR 6.75 28.54B
BNTX BIONTECH SE-ADR N/A 26.20B
NTRA NATERA INC N/A 22.42B
BIIB BIOGEN INC 8.48 19.66B
SMMT SUMMIT THERAPEUTICS INC N/A 16.01B

About RNXT

Company Profile

RNXT logo image RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Company Info

RENOVORX INC

2570 W. El Camino Real, Ste. 320,

Mountain View CALIFORNIA US

CEO: Shaun R. Bagai

Employees: 10

RNXT Company Website

RNXT Investor Relations

Phone: 14088002649

RENOVORX INC / RNXT FAQ

What is the stock price of RENOVORX INC today?

The current stock price of RNXT is 1.37 USD. The price decreased by -1.44% in the last trading session.


What is the ticker symbol for RENOVORX INC stock?

The exchange symbol of RENOVORX INC is RNXT and it is listed on the Nasdaq exchange.


On which exchange is RNXT stock listed?

RNXT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RENOVORX INC stock?

10 analysts have analysed RNXT and the average price target is 5.48 USD. This implies a price increase of 300.18% is expected in the next year compared to the current price of 1.37. Check the RENOVORX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RENOVORX INC worth?

RENOVORX INC (RNXT) has a market capitalization of 50.10M USD. This makes RNXT a Micro Cap stock.


How many employees does RENOVORX INC have?

RENOVORX INC (RNXT) currently has 10 employees.


What are the support and resistance levels for RENOVORX INC (RNXT) stock?

RENOVORX INC (RNXT) has a support level at 1.19 and a resistance level at 1.41. Check the full technical report for a detailed analysis of RNXT support and resistance levels.


Should I buy RENOVORX INC (RNXT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RENOVORX INC (RNXT) stock pay dividends?

RNXT does not pay a dividend.


When does RENOVORX INC (RNXT) report earnings?

RENOVORX INC (RNXT) will report earnings on 2025-08-13.


What is the Price/Earnings (PE) ratio of RENOVORX INC (RNXT)?

RENOVORX INC (RNXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).


What is the Short Interest ratio of RENOVORX INC (RNXT) stock?

The outstanding short interest for RENOVORX INC (RNXT) is 0.81% of its float. Check the ownership tab for more information on the RNXT short interest.


RNXT Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to RNXT. When comparing the yearly performance of all stocks, RNXT is one of the better performing stocks in the market, outperforming 88.66% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RNXT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RNXT. No worries on liquidiy or solvency for RNXT as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RNXT Financial Highlights

Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.43%
ROE -77.21%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-14.29%
Sales Q2Q%N/A
EPS 1Y (TTM)50%
Revenue 1Y (TTM)N/A

RNXT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to RNXT. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners2.85%
Ins Owners1.28%
Short Float %0.81%
Short Ratio1.61
Analysts
Analysts82
Price Target5.48 (300%)
EPS Next Y24.35%
Revenue Next YearN/A